Clinical diagnosis and newborn screening for primary immunodeficiencies (PIDDs) is described. The PIDDs include X-linked chronic granulomatous disease (X-CGD), X-linked lymphoproliferative syndrome (XLP1; SH2D1A deficiency), familial hemophagocytic lymphohistiocytosis 2 (FHL2), ataxia telangiectasia (AT), common variable immunodeficiency (CVID; B-cell dysfunctions), severe combined immunodeficiency (SCID), adenosine deaminase (ADA) deficiency, and dedicator of cytokinesis 8 (DOCKS) deficiency. Additionally, cell specific markers for platelets (CD42), natural killer (NK) cells (CD56), and T cells (CD3epsilon and CD3delta) can be used as secondary markers to provide support for diagnosis of disease.

The present disclosure pertains to compositions with reduced residual amount of lipases and methods of making such compositions. In particular, it pertains to compositions and methods of such making compositions by depleting the compositions of certain lipases, such as, liver carboxylesterase B-1-like protein and liver carboxylesterase 1-like protein.

The present application provides methods and systems for identifying host cell protein impurities which have enzymatic activities in biopharmaceutical products and in samples during manufacturing processes. The present application provides various activity-based probes to characterize different enzyme classes of host cell protein impurities including probes containing functionalized molecules with reporter or affinity-based tags.

Methods for isolating proteins from a honey sample are provided. The methods include contacting the honey sample with a substrate functionalized with one or more reactive dyes and recovering proteins associated with the substrate. Methods for detecting proteins in a honey sample and assessing the risk of colony collapse disorder are also provided.

The present invention discloses mass spectrometry (MS)-based methods and tagging reagents for qualitative and quantitative analysis of post-translational modified (PTM) proteins in biological and clinical samples. The present invention utilizes thiol-containing tagging reagents which are able to bind to or derivatize biomolecules, preferably post-translational modified (PTM) polypeptides such as citrullinated and homocitrullinated polypeptides. The tagging reagents are preferably biotin-derived tags able to react with a side chain of the modified polypeptides.

The present disclosure provides methods of identifying or certifying an animal that consumed a traceable diet comprising a C.sub.1 metabolizing microorganism.

Volatile organic chemicals emitted by a shell egg embryo are used to identify the fertility, viability, and sex of the shell egg embryo. Shortly after the egg is laid, the egg is isolated in a vapor-tight compartment so that a vapor containing volatile organic chemicals emitted by the shell egg embryo collect in the headspace of the compartment. The chemicals in the vapor are analyzed to construct a chemical profile of the shell egg embryo, and then the chemical profile of the shell egg embryo vapor is loaded into a previously developed model. Based on the data generated by the model, the shell egg is embryo is predicted to be an alive male, an alive female, an infertile egg, or an egg containing a dead embryo.

Bead-based assays for measuring protein biomarkers of proteolytic activity in biological systems are disclosed. In an embodiment, an assay involves incubating a sample containing multiple fragments of a naturally occurring protein with a bead array and subsequently analyzing individual reactive sites of the bead array by mass spectrometry.

Materials and methods for detecting and treating Coccidioidomycosis (Valley Fever) are provided herein. For example, materials and methods for enriching and detecting biomarker antigens (e.g., polypeptides and/or glycans) from Coccidioides immitis and Coccidioides posadasii, the fungi that cause Valley Fever, are described herein, as are methods for treating an individual for Valley Fever based on the results of the described detection methods.

The invention relates to methods and compositions for detecting colorectal cancer and colorectal polyps by measurement of metabolites in bodily fluids such as urine, including diacetylspermine and kynurenine.